Myeloproliferative Diseases

The Parkville Integrated Haematology, Myeloproliferative Disease (MPD) Service is a collaboration between a team of four expert clinicians within this field, led by Dr Kate Burbury, with multidisciplinary, supportive care and research teams, to provide comprehensive, coordinated and leading-edge care for patients.

This patient-centred service offers the complete spectrum of care for patients with MPD from diagnosis, staging, monitoring, developing an evidence-based approach to treatment and novel therapies through clinical trials.

Our comprehensive clinical trials and research programmes is dedicated to developing new drugs and bringing them to our patients.



Chronic myeloid leukaemia (CML)
Polycythaemia vera (PV)
Essential thrombocythaemia (ET)
Myelofibrosis (primary and post PV/ET)
Chronic neutrophilic leukaemia (CNL)
Systemic mastocytosis (SM)
Hypereosinophilic syndromes (HES) including chronic eosinophilic leukaemia (CEL)
Myeloproliferative-myelodysplastic overlap syndromes (MPN/MDS)

Related experts


Our clinics are scheduled for Monday afternoon, Tuesday afternoon and Friday morning.

Clinical Trials

Patient care is the focus of what we do.

We are committed to state-of-the-art research, that will allow pursuit of novel therapies and management strategies for your condition.

We have an active clinical trials program which offers a wide range of advanced research treatments for many of our patients.

If you would like to participate or have questions about clinical trials, speak to your specialist.


For patients

We understand how stressful and difficult cancer can be. Your team of experts are dedicated and sensitive to your individual health and wellbeing needs – we are here to help.

You will need a referral from your GP or medical practitioner to access this service. 

For health professionals

Please address all new referrals to Kate Burbury. For urgent referrals, please contact the haematology on-call via the switchboard 03 8559 5000.

Find our more about referrals to Peter Mac.